GOSS EBITDA | GOSSAMER BIO, INC.

GOSSAMER BIO, INC. (GOSS) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$26.07M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA -$44.86M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA -$46.03M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$49.11M*; Operating income -$49.11M; Depreciation and amortization $6.00K*.

Complete source-backed ebitda history.

Available history: 2018-03-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$26.07M	(m)	$9.24M	(m)	$0.00*	-$39.42M*	(m)	(m)	(m)	(m)
2026-03-31	Reported	-$44.86M	(m)	(m)	(m)	-264.59%	$0.00	-$38.72M	(m)	(m)	(m)	(m)
2025-12-31	Reported	-$46.03M	(m)	(m)	(m)	-333.60%	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$49.11M*	-$49.11M	$6.00K*	$13.29M	-369.40%*	$0.00*	-$36.17M*	(m)	(m)	(m)	$0.00
2025-06-30	Reported	-$38.76M*	-$38.77M	$6.00K*	$11.49M	-337.36%*	$53.00K*	-$47.06M*	(m)	(m)	(m)	$0.00
2025-03-31	Reported	-$36.8M	(m)	(m)	(m)	-372.17%	$26.00K	-$39.72M	(m)	(m)	(m)	(m)
2024-12-31	Reported	-$36.02M	(m)	(m)	(m)	-384.05%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$33.72M	(m)	(m)	(m)	-355.69%	$0.00*	-$32.03M*	(m)	(m)	(m)	-$1.13M
2024-06-30	Reported	$52.39M	(m)	(m)	(m)	54.66%	$0.00*	$116.35M*	(m)	(m)	(m)	$4.43M
2024-03-31	Reported	-$41.7M	(m)	(m)	(m)	(m)	$0.00	-$52.30M	(m)	(m)	(m)	(m)
2023-12-31	Reported	-$48.74M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$40.09M	(m)	(m)	(m)	(m)	$0.00*	-$34.49M*	(m)	(m)	(m)	$0.00
2023-06-30	Reported	-$45.8M	(m)	(m)	(m)	(m)	$0.00*	-$38.25M*	(m)	(m)	(m)	$0.00
2023-03-31	Reported	-$47.48M	(m)	(m)	(m)	(m)	$0.00	-$52.99M	(m)	(m)	(m)	(m)
2022-12-31	Reported	-$53.9M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$55.52M	(m)	(m)	(m)	(m)	$31.00K*	-$37.00M*	(m)	(m)	(m)	(m)
2022-06-30	Reported	-$53.37M	(m)	(m)	(m)	(m)	$120.00K*	-$48.82M*	(m)	(m)	(m)	(m)
2022-03-31	Reported	-$53.89M	(m)	(m)	(m)	(m)	$157.00K	-$53.48M	(m)	(m)	(m)	(m)
2021-12-31	Reported	-$51.21M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$55.16M	(m)	(m)	(m)	(m)	$523.00K*	-$42.03M*	(m)	(m)	(m)	(m)
2021-06-30	Reported	-$55.2M	(m)	(m)	(m)	(m)	$138.00K*	-$47.45M*	(m)	(m)	(m)	(m)
2021-03-31	Reported	-$52.79M	(m)	(m)	(m)	(m)	$802.00K	-$58.90M	(m)	(m)	(m)	(m)
2020-12-31	Reported	-$59.72M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$53.20M*	-$53.57M	$365.00K*	(m)	(m)	$299.00K*	-$44.93M*	(m)	(m)	(m)	(m)
2020-06-30	Reported	-$64.99M*	-$65.34M	$350.00K*	(m)	(m)	$441.00K*	-$42.40M*	(m)	(m)	(m)	(m)
2020-03-31	Reported	-$54.64M	(m)	(m)	(m)	(m)	$513.00K	-$52.30M	(m)	(m)	(m)	(m)
2019-12-31	Reported	-$55.5M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$49.73M*	-$49.99M	$251.00K*	(m)	(m)	$711.00K*	-$36.11M*	(m)	(m)	(m)	(m)
2019-06-30	Reported	-$46.14M*	-$46.35M	$205.00K*	(m)	(m)	$1.38M*	-$36.81M*	(m)	(m)	(m)	(m)
2019-03-31	Reported	-$33.85M	(m)	(m)	(m)	(m)	$347.00K	-$27.77M	(m)	(m)	(m)	(m)
2018-12-31	Reported	-$39.67M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$49.90M*	-$50.02M	$125.00K*	(m)	(m)	$1.72M*	-$15.52M*	(m)	(m)	(m)	(m)
2018-06-30	Reported	-$33.00M*	-$33.04M	$32.00K*	(m)	(m)	$941.00K*	-$6.80M*	(m)	(m)	(m)	(m)
2018-03-31	Reported	-$26.12M	(m)	(m)	(m)	(m)	$511.00K	-$3.71M	(m)	(m)	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$170.7M	(m)	(m)	(m)	-352.18%	$79.00K	-$171.27M	(m)	(m)	(m)	-$88.00K
2024-12-31	Reported	-$59.09M	(m)	(m)	(m)	-51.51%	$0.00	-$3.47M	(m)	(m)	(m)	$893.00K
2023-12-31	Reported	-$182.15M	(m)	(m)	(m)	(m)	$0.00	-$159.16M	(m)	(m)	(m)	$0.00
2022-12-31	Reported	-$216.76M	(m)	(m)	(m)	(m)	$410.00K	-$187.03M	(m)	(m)	(m)	$0.00
2021-12-31	Reported	-$214.38M	(m)	(m)	(m)	(m)	$1.55M	-$188.89M	(m)	(m)	(m)	(m)
2020-12-31	Reported	-$232.55M	(m)	(m)	(m)	(m)	$1.50M	-$176.36M	(m)	(m)	(m)	(m)
2020-09-30	Rolling	(m)	-$229.66M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-06-30	Rolling	(m)	-$226.08M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-03-31	Rolling	(m)	-$207.09M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-12-31	Reported	-$185.22M	(m)	(m)	(m)	(m)	$2.97M	-$144.83M	(m)	(m)	(m)	$0.00
2019-12-31	Rolling	(m)	-$186.14M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Rolling	(m)	-$170.16M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-06-30	Rolling	(m)	-$170.20M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-03-31	Rolling	(m)	-$156.88M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-12-31	Reported	-$148.7M	(m)	(m)	(m)	(m)	$3.49M	-$51.04M	(m)	(m)	(m)	$0.00
2018-12-31	Rolling	(m)	-$148.99M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-12-31	Reported	(m)	-$6.65M	(m)	(m)	(m)	(m)	-$5.75M	(m)	(m)	(m)	$0.00

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Cogent Biosciences, Inc. (COGT)	United States	$5.450B	-17.61
PTC THERAPEUTICS, INC. (PTCT)	United States	$5.199B	-177.07
Dianthus Therapeutics, Inc. /DE/ (DNTH)	United States	$5.082B	-27.79
Erasca, Inc. (ERAS)	United States	$5.073B	-19.96
Oruka Therapeutics, Inc. (ORKA)	United States	$5.663B	-43.76
Travere Therapeutics, Inc. (TVTX)	United States	$5.712B	-123.10
Mirum Pharmaceuticals, Inc. (MIRM)	United States	$5.798B	-8.81
Veradermics, Inc (MANE)	United States	$4.839B
Edgewise Therapeutics, Inc. (EWTX)	United States	$4.470B	-22.23
Amneal Pharmaceuticals, Inc. (AMRX)		$6.326B	25.62